Prognostic Value of Thyroid Transcription Factor-1 Expression in Patients with Advanced Lung Adenocarcinoma

Overview

Journal In Vivo

Specialty Oncology

Date 2018 Oct 24

PMID 30348718

Citations 4

Authors

Rolandas Zablockis

Edvardas Zurauskas

Edvardas Danila

Vygantas Gruslys

Affiliations

Soon will be listed here.

Abstract

Background/aim: The prognostic role of thyroid transcription factor-1 (TTF1) in advanced lung cancer is not clearly established. The present study aimed to evaluate the associations between clinicopathological characteristics, TTF1 expression, and overall survival (OS) of patients with advanced lung adenocarcinoma.

Materials And Methods: One hundred and seventy-two patients were enrolled in this retrospective study. OS was assessed according to immunohistochemical TTF1 expression in lung adenocarcinoma tissue, age, gender, performance status (PS), smoking history and status, disease stage, tumor differentiation, epidermal growth factor receptor (EGFR) mutation and EGFR tyrosine kinase inhibitor (TKI) treatment status.

Results: The OS time was longer (p<0.001) for patients with TTF1 expression than for patients without TTF1 expression (13.0 vs. 5.0 months, respectively). A multivariate analysis confirmed that worse PS [hazard ratio (HR)=2.13, p<0.001], poor histological differentiation (HR=2.02, p=0.001), wild-type EGFR status (HR=3.08, p<0.001) and negative TTF1 expression (HR=1.97, p=0.001) were independent predictors of worse prognosis.

Conclusion: TTF1 expression is an independent predictor of survival of patients with advanced lung adenocarcinoma.

Citing Articles

Detection of EGFR gene polymorphisms in non-small cell lung cancer Egyptian patients: a case-control study.

El-Khawaga O, Al-Azzawy M, Elsaid A, Refaat S, El-Dawa A Genes Environ. 2023; 45(1):32.

PMID: 38008767 PMC: 10680232. DOI: 10.1186/s41021-023-00289-y.

Thyroid transcription factor 1 (TTF-1) negativity as a predictor of unfavorable response to EGFR-TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations.

Ding X, Shi W, Han B, Chen H, Li J, An J Thorac Cancer. 2023; 14(29):2934-2940.

PMID: 37605791 PMC: 10569904. DOI: 10.1111/1759-7714.15079.

Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer.

Nakao A, Inoue H, Ikeuchi N, Igata F, Aoyama T, Hamasaki M J Clin Med. 2023; 12(1).

PMID: 36614938 PMC: 9821382. DOI: 10.3390/jcm12010137.

LncRNA LINC00511 plays an oncogenic role in lung adenocarcinoma by regulating PKM2 expression via sponging miR-625-5p.

Xue J, Zhang F Thorac Cancer. 2020; 11(9):2570-2579.

PMID: 32716147 PMC: 7471024. DOI: 10.1111/1759-7714.13576.

References

Tan D, Li Q, Deeb G, Ramnath N, Slocum H, Brooks J . Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003; 34(6):597-604. DOI: 10.1016/s0046-8177(03)00180-1. View

Nordquist L, Simon G, Cantor A, Alberts W, Bepler G . Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest. 2004; 126(2):347-51. DOI: 10.1378/chest.126.2.347. View

Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T . EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol. 2005; 29(5):633-9. DOI: 10.1097/01.pas.0000157935.28066.35. View

Barlesi F, Pinot D, Legoffic A, Doddoli C, Chetaille B, Torre J . Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer. 2005; 93(4):450-2. PMC: 2361585. DOI: 10.1038/sj.bjc.6602717. View

Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S . Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol. 2005; 23(25):6240-8. DOI: 10.1200/JCO.2005.06.866. View

Berghmans T, Paesmans M, Mascaux C, Martin B, Meert A, HALLER A . Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol. 2006; 17(11):1673-6. DOI: 10.1093/annonc/mdl287. View

Goldstraw P, Crowley J, Chansky K, Giroux D, Groome P, Rami-Porta R . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706-14. DOI: 10.1097/JTO.0b013e31812f3c1a. View

Smith G, Chadwick B, Willmore-Payne C, Bentz J . Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol. 2007; 61(4):487-93. DOI: 10.1136/jcp.2007.051425. View

Barletta J, Perner S, Iafrate A, Yeap B, Weir B, Johnson L . Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2008; 13(8B):1977-1986. PMC: 2830395. DOI: 10.1111/j.1582-4934.2008.00594.x. View

10.

Li C, Marek M, Guclu S, Kim Y, Meshref M, Qin S . Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma. J Cancer. 2011; 2:52-61. PMC: 3020361. DOI: 10.7150/jca.2.52. View

11.

Felip E, Gridelli C, Baas P, Rosell R, Stahel R . Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol. 2011; 22(7):1507-1519. DOI: 10.1093/annonc/mdr150. View

12.

Donnem T, Bremnes R, Busund L, Andersen S, Pezzella F . Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer. J Thorac Dis. 2012; 4(2):212-3. PMC: 3378213. DOI: 10.3978/j.issn.2072-1439.2012.03.02. View

13.

Osarogiagbon R . Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM. J Thorac Dis. 2012; 4(2):214-6. PMC: 3378237. DOI: 10.3978/j.issn.2072-1439.2012.03.06. View

14.

Mani H, Zander D . Immunohistochemistry: applications to the evaluation of lung and pleural neoplasms: part 1. Chest. 2012; 142(5):1316-1323. DOI: 10.1378/chest.11-3327. View

15.

Brunnstrom H, Johansson L, Jirstrom K, Jonsson M, Jonsson P, Planck M . Immunohistochemistry in the differential diagnostics of primary lung cancer: an investigation within the Southern Swedish Lung Cancer Study. Am J Clin Pathol. 2013; 140(1):37-46. DOI: 10.1309/AJCP50RDXSCSBTBO. View

16.

Gahr S, Stoehr R, Geissinger E, Ficker J, Brueckl W, Gschwendtner A . EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer. 2013; 109(7):1821-8. PMC: 3790166. DOI: 10.1038/bjc.2013.511. View

17.

Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L . 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014; 25(8):1475-84. DOI: 10.1093/annonc/mdu123. View

18.

Shanzhi W, Yiping H, Ling H, Jianming Z, Qiang L . The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas. PLoS One. 2014; 9(4):e95479. PMC: 3990660. DOI: 10.1371/journal.pone.0095479. View

19.

Haaland B, Tan P, de Castro Jr G, Lopes G . Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol. 2014; 9(6):805-11. PMC: 4219539. DOI: 10.1097/JTO.0000000000000156. View

20.

Kim H, Choi E, Jin H, Shin K . Relationship between EGFR mutations and clinicopathological features of lung adenocarcinomas diagnosed via small biopsies. Anticancer Res. 2014; 34(6):3189-95. View